经动脉化疗栓塞治疗单个肝细胞癌小于5 cm的患者的临床结果

StephenW

Korean J Intern Med. 2018 Oct 26. doi: 10.3904/kjim.2018.058. [Epub ahead of print]
Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization.
Baek MY1, Yoo JJ2, Jeong SW1, Jang JY1, Kim YK1, Jeong SO1, Lee SH3, Kim SG2, Cha SW1, Kim YS2, Cho YD1, Kim HS3, Kim BS1, Kim YJ4, Park SY5.
Author information
Abstract
Background/Aims:

Transarterial chemoembolization (TACE) is performed for single hepatocellular carcinoma (HCC) that are not eligible for surgery or ablation therapy. We investigated the clinical outcomes of patients with a single HCC ≤ 5 cm treated with TACE.
Methods:

This study analyzed 175 consecutive patients who underwent TACE as an initial treatment for single HCC ≤ 5 cm. Predictive factors for complete response (CR), recurrence after CR, and overall survival (OS) were evaluated.
Results:

Total 119 patients (68%) achieved CR after TACE. Tumor size < 3 cm and hepatitis B virus infection were significant predictors of CR (p < 0.05). Recurrent HCC was detected in 73 patients (61.3%) after CR. Age > 65 years and absence of liver cirrhosis were predictive factors for non-recurrence after CR (p < 0.05). The OS for all patients was 80.7 ± 5.6 months, and the 1-, 3-, and 5-year OS rates were 88.1%, 64.8%, and 49.9%, respectively. In multivariate analysis for OS, CR (hazard ratio [HR], 0.467; 95% confidence interval [CI], 0.292 to 0.747) and Child class A (HR, 0.390; 95% CI, 0.243 to 0.626) were significant factors. The OS for the CR and Child class A group were 92 and 93.6 months, respectively, and that of the non-CR and Child B, C group were 53.3 and 50.7 months, respectively (p < 0.001).
Conclusions:

TACE can be a valid treatment in patients with a single HCC ≤ 5 cm not suitable for curative treatment, especially in patients with Child class A and CR after TACE.
KEYWORDS:

Carcinoma, hepatocellular; Chemoembolization, therapeutic; Survival

PMID:
    30360019
DOI:
    10.3904/kjim.2018.058

StephenW

韩国J实习生。 2018年10月26日doi：10.3904 / kjim.2018.058。 [提前打印]
经动脉化疗栓塞治疗单个肝细胞癌小于5 cm的患者的临床结果。
BAEK MY1，柳JJ2，郑某SW1，张JY1，金YK1，郑某SO1，李SH3，金SG2，茶SW1，金YS2，赵YD1，金HS3，金BS1，金YJ4，公园SY5。
作者信息
抽象
背景/目的：

对不适合手术或消融治疗的单个肝细胞癌（HCC）进行经动脉化学栓塞（TACE）。我们调查了用TACE治疗的单个HCC≤5cm患者的临床结果。
方法：

本研究分析了175例接受TACE治疗的单个HCC≤5cm的初始治疗患者。评估完全反应（CR），CR后复发和总生存（OS）的预测因素。
结果：

TACE后共119名患者（68％）达到CR。肿瘤大小<3 cm和乙型肝炎病毒感染是CR的显着预测因子（p <0.05）。 CR后73例患者（61.3％）检出复发性HCC。年龄> 65岁且无肝硬化是CR后非复发的预测因素（p <0.05）。所有患者的OS均为80.7±5.6个月，1年，3年和5年OS率分别为88.1％，64.8％和49.9％。在OS的多变量分析中，CR（风险比[HR]，0.467; 95％置信区间[CI]，0.292至0.747）和Child A类（HR，0.390; 95％CI，0.243至0.626）是重要因素。 CR和Child A组的OS分别为92和93.6个月，非CR和Child B，C组的OS分别为53.3和50.7个月（p <0.001）。
结论：

对于单一HCC≤5cm不适合治愈性治疗的患者，TACE可以是一种有效的治疗方法，特别是对于TACE后儿童A级和CR患者。
关键词：

癌，肝细胞;化学栓塞，治疗;生存

结论：
    30360019
DOI：
    10.3904 / kjim.2018.058

StephenW

http://kjim.org/upload/kjim-2018-058.pdf